![](/img/cover-not-exists.png)
Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system
Aljoscha S. Neubauer, Frank G. Holz, Stefan Sauer, Timo Wasmuth, Christoph Hirneiss, Anselm Kampik, Wolfgang SchraderVolume:
32
Year:
2010
Language:
english
Pages:
14
DOI:
10.1016/j.clinthera.2010.07.010
File:
PDF, 145 KB
english, 2010